Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

67
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
67
Translation01:31

Translation

159.8K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
159.8K
Translation01:31

Translation

21.9K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
21.9K
Smooth Endoplasmic Reticulum01:21

Smooth Endoplasmic Reticulum

8.7K
Smooth endoplasmic reticulum or smooth ER is a sub-organelle with specialized functions in animal cells and plant cells. It is often associated with the tubule morphology of the endoplasmic reticulum.
The ER provides optimal conditions for synthesizing steroid hormones and lipids, such as phospholipids and triglycerides. Traditionally, lipid metabolism was considered to be a smooth ER function. However, there is no direct evidence to prove that rough ER is completely excluded from lipid...
8.7K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

1.0K
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.0K
Alternative RNA Splicing02:18

Alternative RNA Splicing

26.2K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
26.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DDX3X overexpression in mice can cause rapid tissue-specific toxicity and mortality.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Salt-Mediated Electro-Deformation of AAV Capsids Revealed by Nanopipette-Based Single-Particle Analysis.

Analytical chemistry·2026
Same author

FRRS1L gene replacement ameliorates disease phenotypes in the mouse model of developmental and epileptic encephalopathy 37.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

An AAV vector for glial cells.

Nature biotechnology·2026
Same author

Ring-Electrode AC Plasmonic Nanopore Sensing for DNA Load Characterization of Single Adeno-Associated Viruses.

Sensors (Basel, Switzerland)·2026
Same author

Author Correction: Ontogeny and transcriptional regulation of Thetis cells.

Nature·2026

Related Experiment Video

Updated: Mar 26, 2026

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome
06:57

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome

Published on: September 13, 2020

4.5K

Rett Syndrome: Crossing the Threshold to Clinical Translation.

David M Katz1, Adrian Bird2, Monica Coenraads3

  • 1Departments of Neurosciences and Psychiatry, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA.

Trends in Neurosciences
|February 3, 2016
PubMed
Summary

Rett syndrome (RTT) research is advancing due to its genetic cause and symptom reversibility in models. This review covers new biological insights, preclinical findings, and trial design for RTT treatments.

Keywords:
MECP2clinical trialsepigeneticsgene therapyneurodevelopmental disorderspreclinical models

More Related Videos

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.2K
A Rhodopsin Transport Assay by High-Content Imaging Analysis
12:11

A Rhodopsin Transport Assay by High-Content Imaging Analysis

Published on: January 16, 2019

7.0K

Related Experiment Videos

Last Updated: Mar 26, 2026

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome
06:57

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome

Published on: September 13, 2020

4.5K
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.2K
A Rhodopsin Transport Assay by High-Content Imaging Analysis
12:11

A Rhodopsin Transport Assay by High-Content Imaging Analysis

Published on: January 16, 2019

7.0K

Area of Science:

  • Neurobiology
  • Epigenetics
  • Genetics

Background:

  • Rett syndrome (RTT) is a devastating neurodevelopmental disorder with a known monogenic cause.
  • Recent advances highlight the potential for symptom reversibility in preclinical models.
  • Significant interest exists from academic scientists and the pharmaceutical industry.

Purpose of the Study:

  • To review recent advances in understanding the biology of Rett syndrome.
  • To discuss promising preclinical findings and their implications for treatment development.
  • To examine lessons from past clinical trials and elements of trial design for rare disorders.

Main Methods:

  • Literature review of recent scientific publications on Rett syndrome.
  • Analysis of preclinical research, focusing on biological mechanisms and therapeutic targets.
  • Evaluation of clinical trial data and methodologies for rare disease research.

Main Results:

  • The review highlights a convergence of factors supporting RTT treatment development, including a clear genetic basis and reversible symptoms in models.
  • Promising preclinical findings offer potential therapeutic avenues.
  • Lessons learned from past trials and considerations for rare disease trial design are discussed.

Conclusions:

  • Optimism for developing effective Rett syndrome treatments is high due to scientific progress and a strong research infrastructure.
  • Further research into RTT biology and refined clinical trial designs are crucial.
  • Collaboration between researchers, clinicians, and industry is vital for advancing RTT therapies.